Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2458

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622458)

This text provides information about a medication containing Lisdexamfetamine. Each capsule contains Lisdexamfetamine Dimesylate 70 mg (equivalent to 40.5 mg Lisdexamfetamine). It also includes instructions for pharmacists to dispense the Dimesylate capsules along with a medication guide for each patient. The package should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The text mentions to keep the medication out of reach of children.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

This document discusses special populations based on gender (male/female), age (65 years), renal impairment levels (mild, moderate, severe, end-stage renal disease), and a fold change analysis with a 90% confidence interval relative to a reference.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

This text appears to be discussing the changes in Cmax and auc for the medications Guanfacine, Venlafaxine, and Omeprazole. It also mentions fold change and 90% CI, which could be related to the observed differences in pharmacokinetics. The text may be part of a scientific report or study evaluating the relative changes of these drugs compared to a reference.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

FDA Label Image

Figure 4 (Lisdexcaps 05)

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

The text provides information about LS Mean (SE) PERMP Total Scores resulting from a study involving lisdexamfetamine. It includes values from 330 to 250 and mentions a Phacebo condition. There is also a chart showing Time Post-Dose (hours) ranging from 4 to 14.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

This information appears to show the proportion of subjects experiencing relapse or treatment failure over time while being treated with Lisdexamfetamine. The table seems to list different time points in days after randomization and the corresponding percentage of subjects who had a relapse or treatment failure at those points.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.